IK 595
Alternative Names: IK-595Latest Information Update: 18 Jul 2024
At a glance
- Originator Ikena Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Cancer
Most Recent Events
- 31 May 2024 Adverse events data from a Phase-I clinical trials in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 18 Apr 2024 Preclinical trials in Cancer (Combination therapy) in USA (PO), prior to April 2024 (Ikena Oncology pipeline, April 2024)
- 05 Apr 2024 Pharmacodynamics data from preclinical in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)